Clinical trial

Mechanisms for Restoration of Hypoglycemia Awareness

Name
2000023189
Description
To assess if using the hypoglycemic clamp and functional magnetic resonance imaging (fMRI) scanning in hypoglycemia unaware and aware T1DM patients and healthy controls have showed distinct differences in patterns of brain responses. In particular, T1DM patients who are aware of hypoglycemia (T1DM-Aware) have greater activity in sensory integration brain regions (e.g. parietal lobe and caudate nucleus) in response to hypoglycemia, whereas hypoglycemia unaware T1DM patients (T1DM-Unaware) show no detectable changes in brain reward regions during hypoglycemia.
Trial arms
Trial start
2018-11-07
Estimated PCD
2023-08-14
Trial end
2023-08-14
Status
Completed
Phase
Early phase I
Treatment
Continuous Glucose Monitor (CGM)
Continuous Glucose Monitor (CGM)
Arms:
Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months
Other names:
Dexcom G6
Insulin
standard insulin regimen
Arms:
Aim 1: Impact of hypoglycemia on brain connectivity Type 1, Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1, Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months
Size
40
Primary endpoint
Brain glucose levels
3 months
Eligibility criteria
Inclusion Criteria: * Ages \> 18 years * Healthy, non-diabetic control or T1DM * BMI \> 18.0 Exclusion Criteria: * Creatinine \> 1.5 mg/dL * Hct \< 35% for females, \< 39% for males * ALT \> 2.5 X ULN * untreated thyroid disease * uncontrolled hypertension * neurologic disorders * untreated depression or change in antidepressant regimen in last 3 months * use of any anxiolytic medications (benzodiazepine) or antipsychotic medications * greater than 5% change in weight in last 3 months * malignancy * current or recent steroid use in last 3 months * illicit drug use * significant complications related to diabetes (peripheral neuropathy, proliferative retinopathy) * inability to enter MRI (per standard MRI safety guidelines) * for women: pregnancy or breastfeeding
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['EARLY_PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'blinded', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 40, 'type': 'ACTUAL'}}
Updated at
2024-03-07

1 organization

1 product

1 indication

Organization
Yale University
Product
Insulin